A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia  by Arrondel, Christelle et al.
Kidney International, Vol. 65 (2004), pp. 2030–2040
A large tandem duplication within the COL4A5 gene
is responsible for the high prevalence of Alport syndrome
in French Polynesia
CHRISTELLE ARRONDEL, GEORGES DESCHEˆNES, YANNICK LE MEUR, AMANDINE VIAU,
CHRISTOPHE CORDONNIER, ALAIN FOURNIER, STEPHANE AMADEO, MARIE-CLAIRE GUBLER,
CORINNE ANTIGNAC, and LAURENCE HEIDET
Inserm U574, Hoˆpital Necker-Enfants Malades, Universite´ Rene´ Descartes, Paris, France; Service de Ne´phrologie Pe´diatrique,
Hoˆpital Armand-Trousseau, Paris, France; Service de Ne´phrologie, Hoˆpital universitaire Dupuytren, Limoges, France; Service de
Ne´phrologie, Centre Hospitalier territorial, Papeete, Tahiti, Polyne´sie Franc¸aise; Banque d’ADN de Polyne´sie, Papeete, Tahiti,
Polyne´sie Franc¸aise; and Service de ge´ne´tique, Hoˆpital Necker-Enfants Malades, Paris, France
A large tandem duplication within the COL4A5 gene is re-
sponsible for the high prevalence of Alport syndrome in French
Polynesia.
Background. The prevalence of X-linked Alport syndrome,
a progressive inherited nephropathy associated with mutations
in the type IV collagen gene COL4A5, is remarkably high in
French Polynesia.
Methods. A vast clinical, genealogic, and molecular study was
undertaken in Polynesia, based on public records, patients’ in-
terviews, linkage analysis, and mutation screening.
Results and Conclusions. We show that the high frequency
of Alport syndrome in this region is due to a founder mu-
tation that occurred onto a common haplotype shared by
affected and unaffected individuals, the presence of which pre-
cludes indirect molecular diagnosis. We have characterized the
mutation as a tandem duplication of 35 COL4A5 exons, result-
ing in a ∼65% increase in the length of the collagenous do-
main of the a5(IV) chain, which is still able to assemble into
type IV collagen network as shown by immunofluorescence
analysis. That mutation is associated with severe and highly
penetrant ocular symptoms and with uniformly thin glomerular
basememnt membrane (GBM) in male adult patients. How-
ever, the rate of progression of the renal disease is very variable
from one male patient to another, demonstrating the impor-
tance of strong modifier factors. Our results suggest that the
20% to 50% of “missing” COL4A5 mutations in X-linked Al-
port syndrome may be rearrangements similar to that reported
here, which was not detectable by sequencing of either individ-
ual COL4A5 exons or overlapping cDNA fragments. Finally, we
provide the basis for a polymerase chain reaction (PCR) assay
that accurately identifies female carriers and allows adequate
genetic counseling in this population.
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Alport syndrome is an inherited hematuric nephropa-
thy characterized by irregular thinning, thickening and
splitting of the glomerular basement membrane (GBM)
that leads to end-stage renal disease (ESRD), frequently
accompanied by sensorineural deafness and ocular ab-
normalities (anterior lenticonus and macular flecks) [1–
4]. The pathogenesis of the disease has been linked to
defect of type IV collagen, which is the major structural
component of the basement membranes. Each type IV
collagen molecule is composed of three a chains that
share a very similar primary structure: (1) an approx-
imately 25 residue “7S” domain at the amino terminus;
(2) a long collagenous domain of approximately 1400 Gly-
X-Y repeats, which forms the triple helix together with
two other a chains; and (3) an approximately 230 residue
noncollagenous (NC1) domain at the carboxyl terminus,
which is folded into a globular structure. The 7S and NC1
domains are cross-linking domains. Alport syndrom is as-
sociated with mutations in any of the COL4A3, COL4A4,
or COL4A5 genes, encoding the a3, a4, and a5(IV)
chains [5, 6]. These three chains assemble into a a3.a4.a5
collagen network, which is extensively cross-linked by
disulfide bonds and seems essential for long-term stabil-
ity of the GBM [7, 8]. About 85% of the affected fami-
lies exhibit X-linked inheritance of the disease [5]. This
most common form of Alport syndrome, estimated to af-
fect 1 in 5000 to 10,000 males worldwide [9], is caused
by mutations in the X-chromosomal COL4A5 gene, at
Xq22. To date, more than 300 mutations in COL4A5
have been identified [4, 10–12]. COL4A5 is comprised
of 53 coding exons [12, 13] spread over ∼260 kb of ge-
nomic DNA. Major gene rearrangements, detected by
Southern blot analysis, are thought to account for 5%
to 15% of the mutations in X-linked Alport syndrome
[14, 15]. Searches for small mutations, mainly based on
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single-strand conformational polymorphism (SSCP)
analysis of polymerase chain reaction (PCR) amplified
exons followed by nucleotide sequencing of abnormally
migrating PCR products, result in a low mutation detec-
tion rate, varying from 37% to 50% [10, 16, 17]. These mu-
tations are distributed over the entire length of the gene.
Direct DNA sequencing of PCR amplified COL4A5 ex-
ons, using oligonucleotides located further in introns, was
reported to enhance the mutation detection rate to 82%
[12].
ESRD develops in virtually all affected males with X-
linked Alport syndrome. Depending on the rate of pro-
gression to ESRD, two types of Alport syndrome have
been distinguished [9]: (1) a progressive or “juvenile”
type in which ESRD occurs around the age of 20 years,
always before 31 years, and the course is highly stereo-
typed within a given family, and (2) a “nonprogressive”
or “adult” type in which age at ESRD is around 40 years,
and the course is much more diverse, making individual
prognostication impossible.
The prevalence of Alport syndrome in French Polyne-
sia, which comprises 118 islands and atolls strewn across
the eastern South Pacific, is much higher than in any other
part of the world. In this paper, we have investigated the
clinical epidemiology and molecular genetics of Alport
syndrome in French Polynesia.
METHODS
Patients
A large clinical and genealogic study was undertaken
in French Polynesia by Y.L. and G.D. in the early 1990s,
based on patient and family interviews, medical, church,
and state administration records. One thousand and five
hundred individuals were investigated. Blood samples
were collected from 83 individuals, including 76 with a
known Alport syndrome status (11 affected males, 23
unaffected males, 35 affected females and 7 unaffected
females). Informed consent was obtained for all tested in-
dividuals or their parents. A skin biopsy was performed in
an adult male patient, and skin fibroblasts were cultured
as previously described [18].
Linkage and haplotype analysis
DNAs were genotyped at four polymorphic mi-
crosatellite loci covering a ∼6 megabases interval at
Xq22. Markers DXS1191 and DXS8112 [19] are cen-
tromeric to COL4A5, 2B6 is located within the COL4A5
gene [20] and DXS456 [21] is telomeric to COL4A5. Link-
age analysis was carried out using the FASTLINK pack-
age, assuming an X-linked inheritance, a penetrance of
100% in males and 95% in females [22], a gene frequency
of 0.0001, and allowing 0.001 of phenocopies.
Fig. 1. Electron microscopy from a 33-year-old Tahitian male patient
with hematuria, proteinuria and renal failure. A regular thinning of the
glomerular basement membrane is observed in one preserved glomeru-
lus (uranyl acetate-lead citrate, ×5000).
DNA sequencing, Southern blot, and pulsed-field
gel electrophoresis (PFGE) analysis, COL4A5 probes
All coding exons and the 820 bp of the minimal pro-
moter of COL4A5 were PCR-amplified using intronic
primers as in [12], from the DNAs of two affected males.
PCR products were purified by means of the Wizard PCR
prep DNA-purification system (Promega, Charbonnie`re,
France) and directly sequenced in both directions by use
of an Applied Biosystems DNA sequencer (model 373A;
Foster City, CA, USA) and the BigDye terminator cy-
cle sequencing kit (Perkin-Elmer, Courtaboeuf, France),
according to the manufacturer’s instructions. For South-
ern blot analysis, DNA was digested and hybridized as
previously described [14]. High-molecular-weight DNA
was isolated from cultured fibroblasts, and PFGE analysis
was carried out as in [23]. COL4A5 cDNA probes were
previously described [24, 25]. Several genomic probes lo-
cated at regular intervals in COL4A5 introns 1 and 36
were PCR amplified from three PAC clones covering the
COL4A5 gene (RPCI library clones 149D17, 740A11,
and 24A23), which are part of the Homo sapiens chromo-
some X genomic contig (NT 011765) and were purchased
from the Sanger Institute.
RNA extraction, reverse transcription (RT)-PCR,
and Northern blot analysis
RNA from cultured fibroblasts were extracted using
the Rneasy kit (Qiagen, Courtaboeuf, France). cDNA
synthesis and PCR amplification were performed as
in [23]. Seven overlapping cDNA fragments, covering
the entire COL4A5 cDNA and the poly-A tail, were
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Fig. 2. Pedigree of family I and haplotypes of some genotyped family members from one branch of family I. (A) Open squares/circles represent
unaffected individuals, black squares/circles represent affected individuals, and gray squares/circles represent individuals with an unknown clinical
status. Open circles with a central dot represent obligate carriers with an unknown clinical status. (B) The branch of family I (branch 13) descends
from the affected son of S-L indicated by the arrowhead. Only genotyped individuals from branch 13 are shown. Haplotypes are indicated for 4
polymorphic microsatellite loci, covering a ∼6 megabases interval at Xq22. The marker 2B6 is located within the COL4A5 gene (20). All affected
individuals carry the same haplotype at the COL4A5 locus. However, some unaffected individuals also carry that haplotype (arrows).
amplified using seven pairs of primers (located in exons
1–13, 12–24, 23–30, 29–37, 36–44, 43–50 and 49–51,
respectively) and sequenced. Poly-A RNA were pre-
pared using the mRNA purification kit (Amersham,
Brauschweig, UK) and Northern blot analysis was per-
formed using 1 lg of poly-A RNA, and hybridized with
the Pc4b COL4A5 cDNA probe [25].
RESULTS
Clinical data
Clinical investigations showed a remarkably high
prevalence of Alport syndrome in French Polynesia. An
inventory of 160 Alport syndrome patients (87 females
and 73 males) from different islands was made. The
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Fig. 3. Analysis of the restriction fragment patterns found in a control individual (c) and a Polynesian patient (p), restriction map of the region and
illustration of the proposed mechanisms for the recombination event resulting in the mutated allele. (A) After digestion with NruI, NotI, or SacII
and hybridization with any COL4A5 cDNA probe, restriction fragments were ∼150 kb larger in Polynesian patients than in control DNA. After
digestion with SfiI and hybridization with JZ4, a cDNA probe covering exons 1 to 9, a ∼65 kb fragment was observed in a Polynesian patient in
addition to the normal restriction fragments. (B) The long range restriction map around the COL4A5 gene is from (23); Note: NotI, Nru: NruI, Sac:
SacII, X: XhoI, F: SfiI. COL4A5 exons 1, 2, 3, 9, 36, 37, and 51 are shown by black boxes. For clarity, the other exons are not indicated. The cross
schematizes unequal crossing-over between COL4A5 introns 1 and 36. (C) Schematic representation of the mutant COL4A5 allele resulting from
unequal recombination, containing a tandem gene duplication of ∼130 kb, extending from intron 1 to intron 36. We used several probes located at
regular intervals in intron 1 and in intron 36 to hybridize SfiI-digested DNA, and thereby mapped the most proximal region of intron 1 hybridizing
the abnormal 65 kb fragment to between nt 70,960 and 73,957 of intron 1, and the most distal region of intron 36 hybridizing the abnormal 65 kb
fragment to between nt 14,259 and 25,934 of intron 36. This was consistent with the size of an SfiI junction fragment bounded by the SfiI site in
intron 35 (5′) (F2), and the SfiI site in exon 3 (3′) (F1). After XhoI digestion, a probe covering nt 74,556 to 75,175 of intron 1 and a probe containing
exon 36 hybridized, in addition to the normal fragments, an abnormal 40 kb fragment (not shown), in agreement with a junction fragment bounded
by XhoI sites in intron 31 (5′) (X2) and in intron 1 (3′) (X1).
diagnosis of Alport syndrome was based on hematuria
(N = 151), association of end-stage renal failure (ESRF),
and family history suggesting Alport syndrome (N = 5),
or solely on evidence of anterior lenticonus (N = 4). Al-
port syndrome was the cause of ESRF in 21% (17 out
of 80) of the patients undergoing dialysis or having re-
ceived a kidney graft in 1991, and in 18% (37 out of
200) in 2003. Age at ESRD in affected males (30 male
patients have reached ESRD) varied from 14 years to
44 years. The median renal survival rate in males was
31 years. In females, the renal survival was 100% until
the age of 45 years. Seven female patients have reached
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ESRF, between the age of 45 and 60 years. Eighty-one pa-
tients (41 males and 40 females) were tested for hearing
loss, which was detected in 29 (23 males and 6 females)
of them. Although all affected males displayed the car-
dinal symptoms of Alport syndrome, some unusual clini-
cal and morphologic features were consistently observed.
The ocular symptoms were remarkably severe, as anterior
lenticonus was present in 100% of male patients reaching
ESRD and was responsible for severe visual impairment
in half, necessitating surgical lens removal. By compari-
son, lenticonus was found in only 14% of males in a large
European cohort of 250 X-linked Alport syndrome fam-
ilies, mostly without significant consequences for visual
acuity [4]. Six renal biopsies (performed in three adult
males, two 15-year-old boys, and one 12-year-old-boy)
were studied by electron microscopy and showed diffuse
and uniform thinning of the GBM (Fig. 1). Five biopsies
were studied by immunofluorescence with antibodies di-
rected against the a3, the a4, and the a5(IV) collagen
chains, respectively, and showed a normal GBM staining
for the three chains.
Pedigrees and haplotype analysis
After genealogic investigations, all individuals could
be placed in pedigrees of two large families (Fig. 2A, the
pedigree of family I) comprising seven generations. The
disease was clearly X-linked. It was much more severe in
males and there was no father-to-son transmission. Both
families originated from Rimatara, a tiny island from the
Austral archipelago, 1100 km away from the capital. Fam-
ily I descends from one individual (S-L), a French whaler
who was shipwrecked in 1870 in Tuamotu islands, and
settled in Rimatara, where he married a Polynesian lady
with whom he had 14 children, four (two females and two
males) of whom were affected with Alport syndrome. The
study of the distribution of the patients within the differ-
ent generations of the pedigree showed a consistent in-
crease of the frequency of the disease, with a geometric
progression.
DNAs from 83 individuals, including 76 with a known
Alport syndrome status, belonging to 4 branches of family
I (one branch from each of S-L’s affected children) and
to family II, were genotyped at four microsatellite loci
located on either side of, or within, COL4A5 at Xq22.
Linkage analysis showed a two point maximum LOD
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 4. Schematic representation of the 3′ end of the normal (top) and mutated (bottom) COL4A5 RNAs, reverse transcription-polymerase chain
reaction (RT-PCR) amplification of patients (p) and control (c) COL4A5 fibroblast cDNA with a forward primer located in exon 34 and a reverse
primer in exon 2, sequencing analysis of the amplified cDNA in a Polynesian patient, Northern blot analysis of fibroblast RNAs from control (c)
and from a male Polynesian patient (p) after hybridization with a COL4A5 cDNA probe. (A) COL4A5 exons are represented by boxes and are
numbered. In the mutant RNA, a splicing occurred between exon 36 and exon 2. The locations of the primers used for RT-PCR amplification of
the mutant cDNA shown in (B) are indicated by arrows. (B) RT-PCR amplification of fibroblast RNA from a male patient generated a 303 bp
mutant specific product. RT+ with reverse transcriptase; RT− without reverse transciptase. (C) Sequencing of this product showed that nt 3246
in the patient COL4A5 transcript was followed by nt 82, corresponding to the fusion of exon 36 and exon 2. (D) Northern blot analysis showed a
transcript of ∼6.5 kb in the control and a transcript of ∼9.6 kb in the patient.
score of 7.74 at hmax = 0 between the disease locus and
the COL4A5 intragenic marker 2B6. Haplotype analy-
sis showed that the same haplotype was carried by all
affected males and obligatory carrier females but also
by some unaffected individuals (Fig. 2B). This suggested
that a COL4A5 mutation occurred recently onto a haplo-
type that was already frequent in Rimatara. This finding
prevented genetic counseling by haplotype analysis and
necessitated the characterization of the mutation in order
to provide a diagnosis test.
MUTATION ANALYSIS
Search for small mutation by sequencing and Southern
blotting analysis
All 53 coding exons (exons 1 to 51, 41A, and 41B)
together with the 820 bp of the minimal promoter of
COL4A5, amplified from the DNAs of two affected
males, were sequenced. This approach did not yield any
DNA variants. Southern blot analysis of EcoRI- and PstI-
digested DNA from an affected male hybridized with
overlapping COL4A5 cDNA probes did not show any
abnormal restriction patterns. To look for splicing muta-
tion located outside the immediate exonic regions, RT-
PCR was performed using total RNA isolated from skin
fibroblast cultures (known to express COL4A5 [26]) of
an affected male. Seven overlapping cDNA fragments,
covering the entire COL4A5 cDNA and the poly-A tail,
were amplified and sequenced. No splice variants were
detected.
PFGE analysis
Considering the possibility of a complex rearrange-
ment of the gene, we prepared high molecular weight
DNA from skin fibroblasts from an affected male and
performed PFGE mapping at the COL4A5 locus. Di-
gestion with NotI, NruI, or SacII and hybridization with
any COL4A5 probe showed restriction fragments which
were ∼150 kb larger in patient than in control fibroblast
DNA (Fig. 3A). After digestion of the patient’s DNA with
SfiI and hybridization with JZ4, covering exons 1 to 9, a
∼65 kb fragment was observed in addition to the
normal restriction fragments (Fig. 3A). These results
suggested that part of COL4A5 was duplicated, this
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Fig. 5. EcoRI restriction pattern of genomic DNA of a patient (p) and control (c), polymerase chain reaction (PCR) amplification of genomic
DNA and DNA sequencing analysis of the COL4A5 mutation in a male Polynesian patient. (A) After digestion with EcoRI and hybridization
with the COL4A5 int A probe, located at nt 74,556 to 75,175 of intron 1, a 7.2 kb junction fragment was observed in the patient’s DNA in addition to the
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duplication being localized within the SacII fragment that
contains the entire length of COL4A5 and extends 1.8 kb
upstream and 39 kb downstream of the gene (Fig. 3B,
top). Since exon 2- (but not exon 1−) and exon 36−
(but not exon 37−) probes hybridized the same 65 kb
abnormal SfiI fragment in the patient’s DNA, and be-
cause COL4A5 introns 1 and 36 are large (99 kb and 29
kb, respectively) and contain several repetitive elements,
we hypothesized that a duplication of part of COL4A5
may have occurred due to unequal crossover between
two nonsister chromatids as shown in Figure 3B. We used
probes located at regular intervals in intron 1 and intron
36 to hybridize SfiI- and XhoI-digested DNA from the
male patient. The restriction patterns were in agreement
with a ∼130 kb duplication including part of intron 1,
exons 2–36, and part of intron 36, located in intron 36
(Fig. 3C).
Patient COL4A5 RNA analysis
The exon-intron structure of COL4A5 shows that exon
36 ends with complete lysine codon and exon 2 starts with
complete alanine codon. Thus, in the Tahitian mutated al-
lele as shown in Figure 3C, splicing between exon 36 and
exon 2 would maintain the reading frame of the mRNA.
To test this hypothesis we performed PCR amplification
of a patient’s and control fibroblast cDNA using a forward
primer in exon 34 and a reverse primer in exon 2 (Fig. 4A,
bottom). A 303 bp product was amplified in the patient
but not in the control (Fig. 4B). Subcloning and sequenc-
ing analysis of this PCR product showed that nt 3246 in
the patient’s COL4A5 transcript was followed by nt 82,
corresponding to the joining exon 36 and exon 2 (Fig. 4C),
with a conservation of the reading frame. RT-PCR using
a forward primer in exon 36 and a reverse primer in exon
9 confirmed these data (not shown). Northern blot analy-
sis with poly-A RNA from patient and control fibroblasts
hybridized with a COL4A5 cDNA probe showed a tran-
script of ∼6.5 kb in the control. In the patient, a single
transcript of ∼9.6 kb was detected (Fig. 4D). This is con-
sistent with a COL4A5 transcript consisting of 88 exons
(exon 1 to 36 followed by exon 2 to 51) (see Fig. 3B,
bottom).
Identification of the duplication junction fragment
and PCR mutation test
A probe covering nt 74,556 to 75,175 of intron 1 (int A
probe) was shown to hybridize a 7.2-kb EcoRI abnormal
fragment in addition to the expected 8.3 kb fragment, in
expected 8.3 kb fragment. (B) Multiplex PCR amplification of genomic DNA with a forward primer located at nt 14,993 of intron 36 and a reverse
primer located at nt 71,896 of intron 1 yielded a 1136 bp product in affected individual (p) but not in control (c), whereas the ∼200 bp microsatelite
marker D17S1843 was amplified in patient and control. (C) Sequencing analysis showed that nt 16,073 of intron 36 is followed by intron 1 sequence
found 27,699 nt upstream of exon 2. Sequence of the mutant allele and the corresponding regions of the normal allele in introns 36 and 1 are aligned.
The box shows the 4 bp sequence that is identical between intron 36 and intron 1, where the recombination occurred.
the patient’s DNA (Fig. 5A). All available DNAs were
tested, and this fragment was found in all affected males
and all obligatory affected females, but not in unaffected
individuals carrying the haplotype associated with the
Alport syndrome phenotype, showing that the presence
of this abnormal fragment was segregating with the dis-
ease phenotype. However, two females, a mother and her
daughter, considered to be affected because they showed
hematuria, did not display the abnormal fragment. These
individuals were thought to represent phenocopies. Con-
sequently, clinical reinvestigation was undertaken, which
in fact showed that the mother has hematuria due to
nephrolithiasis. Further investigations are currently un-
derway to characterize the phenotype in her daughter.
The abnormal 7.2 kb EcoRI fragment recognized by the
int A probe in intron 1 was shown subsequently to also hy-
bridize to a probe covering nt 14,259 to 14,431 of intron 36.
In order to determine precisely the duplication-junction
fragment, we performed PCR amplification using a
forward primer 5′-CCAGAGAAAATTGAGGAGAG-
3′ at nt 14,993 of intron 36 and a reverse primer
5′-ATGTTGAACCATTTAGGAGAA-3′ at nt 71,896 of
intron 1. This yielded a 1136 bp product in affected
individuals (Fig. 5B). Again, all available DNAs were
screened, using a multiplex PCR assay, containing the mi-
crosatellite marker D17S1843 [19] as an internal control.
A PCR product was amplified only in individuals pre-
viously shown to display the abnormal EcoRI fragment
with the int A probe. The comparison of this product
with the corresponding normal sequences showed that
the breakpoint in intron 36 was located at nt 16,073 within
a long interspersed nuclear element 1 (L1). The break-
point in intron 1 was located at nt 71,840, in a 122-bp
nonrepeated sequence. Nucleotide alignment around the
breakpoint showed a 4 bp junctional homology (AAGC)
(Fig. 5C). However, the recombined allele amplified from
affected patients showed a (AGG-) junctional sequence
instead (Fig. 5C).
DISCUSSION
While Alport syndrome accounts for 1% to 2% of pa-
tients reaching ESRD in Europe and 2.3% of the renal
transplant patients in the United States [9], 18% of the
patients currently undergoing dialysis in French Polyne-
sia, are affected with Alport syndrome. The disease is
currently the most prevalent monogenic inherited disor-
der in this area. In the present paper, we show that the
high frequency of Alport in French Polynesia is caused by
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a founder mutation that we have characterized here as a
tandem duplication of 35 COL4A5 exons. This rearrange-
ment was not detectable by exon sequencing or conven-
tional Southern blotting using COL4A5 cDNA probes.
Furthermore, due to the size of the cDNA and the fact
that the duplication, involving exons 2–36, is located in
intron 36, the mutation was not detectable by the se-
quencing of overlapping COL4A5 cDNA fragments. In
the mutant allele, the duplication results in the transcrip-
tion of a 9.6 kb RNA comprised of 88 exons (exon 1 to
36 followed by exon 2 to 51), with a conservation of the
COL4A5 reading frame. In the mutated a5(IV) chain,
the duplication introduces, within the (Gly-Xaa-Yaa) col-
lagenous domain, a 14 amino acid noncollagenous se-
quence, including four cysteines from the disulfide rich 7S
amino-terminal domain (encoded by the 5′ part of exon
2), followed by 1040 additional amino acids of the collage-
nous domain (encoded by the 3′ part of exon 2 to exon 36).
We [27] and others [28, 29] have shown previously that
about one-third of patients affected with X-linked Alport
syndrome normally express the GBM a3.a4.a5(IV) colla-
gen network, whereas COL4A5 mutations are ultimately
responsible for a defective assembly of that network in
two thirds of the patients. A normal immunohistologic
distribution of the collagen chains was reported to be
mostly associated with missense or in-frame mutations,
whereas large rearrangements were shown to be associ-
ated with a lack of a3.a4.a5(IV) network expression [4,
28, 29]. Here, we report a large in frame duplication of
COL4A5 resulting in a 1054 amino acid longer a5(IV)
chain (an increase of ∼65% in the length of the triple
helical domain of the chain) which, surprisingly, is still
able to assemble with a3(IV) and a4(IV) into the GBM
collagen network, as shown by the normal expression of
the a5(IV) chain in the Tahitian patients’ kidneys. A sim-
ilarly mutated a2(I) chain with an aberrantly long, albeit
shorter than that we report here, triple helical domain
was shown to be incorporated into fibrillar procollagen
molecules [30]. Additionally, the fact that the triple heli-
cal domains of type IV collagen molecules naturally com-
prise frequent noncollagenous interruptions, thought to
play a role in flexibility [31], may explain why the inser-
tion of a short noncollagenous sequence does not affect
the assembly of the mutated chain.
Isolated populations where affected individuals are
recently descended from a mutation-bearing founder
usually provide opportunity of studying disease with ho-
mogeneous phenotype, due to little variations created by
allelic heterogeneity, geographic or ethnic variation. Sur-
prisingly, the progression of the renal disease in Polyne-
sian patients, who all bear the same COL4A5 mutation,
varies a lot from one male to another, making it impossi-
ble to classify the disease as either the juvenile or the adult
form of Alport syndrome. This suggests that strong envi-
ronmental and/or genetic factors modify the progression
of the Alport syndrome nephropathy. It will be interest-
ing, in a first attempt, to check whether the level of tran-
scription of the mutant COL4A5 gene in skin fibroblasts
correlates with a slower progression of the disease.
Anterior lenticonus in X-linked Alport syndrome oc-
curs more frequently in patients carrying large COL4A5
deletions, nonsense or frameshift mutations, usually as-
sociated with a lack of expression of a5(IV)-containing
type IV collagen networks [4]. However, ocular symp-
toms were present in all Tahitian males reaching ESRD,
suggesting that the mutant protein is directly responsi-
ble for severe abnormalities of the anterior lens cap-
sule, which normally express all of the a(IV) chains [32].
Another striking feature was the diffuse and uniform
thinning of the GBM in adult Tahitian patients. Diffuse
thinning of the GBM is observed in patients affected with
benign familial hematuria, which is associated with het-
erozygous COL4A3 or COL4A4 mutations [33, 34]. It
may be the only morphologic defect observed in children
affected with Alport syndrome, but, when present in adult
Alport syndrome patients, thinning of the GBM is most
often segmental and associated with thickening and split-
ting. Our data further demonstrate that “thin basement
membrane” is not necessarily associated with good renal
prognosis.
The mechanism responsible for the tandem duplica-
tion we report here is likely to be a non-homologous
recombination due to interchromosomal misalignment.
Recombination between homologous DNA sequences
during meiosis after chromosomal pairing, breakage
and crossover is an essential cellular process. However,
nonequal chromosomal pairing resulting in nonhomol-
ogous recombination is a source of harmful deletions
and duplications and diseases [35]. Hot spots of homolo-
gous recombination between nonallelic, interspersed, or
tandem repeats, or between members of gene families
or pseudogenes, have been observed at the duplication
and deletion breakpoints in a number of human diseases
[35]. In several reported cases, however, break points
occur through nonhomologous end-joining between
repeat-free DNA fragments, or between a repeat and
a repeat-free sequence [36], as is the case in the dupli-
cation we report here. The involvement of short direct
repeats of 2 to 8 bp at the duplication/deletion break
points, such as the 4 bp (AAGC) junctional homol-
ogy which was found here, has been well documented
[37–40]. However, the recombined allele amplified from
Tahitian patients showed a (AGG-) junctional sequence
instead of the (AAGC) sequence. This is consistent with
minor deletions and/or insertions often found at the site
of rearrangements that possibly originate from repair
processes during which free ends of DNA strands are
filled in prior to ligation [41]. Although less common than
recombination due to exonic sequence homology [42–
45], nonhomologous recombination involving introns has
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been previously reported in fibrillar [30] and nonfibrillar
[46] collagens. While we were not able to precisely date
the occurrence of this mutation, it must have occurred
before 1870, and the two reported families are proba-
bly related through the wife of S-L, the French whaler.
Several factors may have led to the progression of the
prevalence of the disease in French Polynesia: the de-
layed onset of renal failure in some males, thereby allow-
ing them to procreate, and the local demographics with a
fertility rate of 5.3 children born per woman at the time
the clinical study was undertaken. In most patients af-
fected with X-linked Alport syndrome, the absence (in
males) or focal distribution (in females) of the a5(IV)
chain, in the GBM as well as in the dermal basement
membrane can be used for rapid and definitive diagnosis,
by immunofluorescence analysis of a simple skin biopsy
[27]. However, in Polynesian patients, the synthesis and
incorporation of the mutated a5(IV) chain into the type
IV collagen network prevents such diagnosis. In addi-
tion, we have shown that the Xq22 haplotype associated
with the disease phenotype is also present in unaffected
individuals, precluding any indirect molecular diagnosis.
Therefore, the mutation analysis and the multiplex PCR-
based test we report here provides the basis for a rapid,
simple, and robust test for Alport syndrome in this area.
It will be especially useful for detection of female carriers
and adequate genetic counseling.
The COL4A5 mutation rate reported in different large
cohort of X-linked Alport syndrome patients [10, 16–17]
is low, suggesting that many mutations are overlooked.
Our report suggests that the 20% to 50% of “missing”
mutations in X-linked Alport syndrome may be large
COL4A5 rearrangements, which cannot be detected by
sequencing of genomic DNA and may escape sequenc-
ing analysis of overlapping cDNA fragments. Families
for which no mutations are found by sequencing analysis
should therefore be tested by PFGE restriction mapping.
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